Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21

THOUSAND OAKS, Calif.: THOUSAND OAKS, Calif., Sept. 8, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from two analyses of the Phase 2 CodeBreaK 100 clinical trial evaluating LUMAKRAS™ (sotorasib), the first and only KRASG12C inhibitor approved in the U.S., in the treatment of previously treated patients with advanced...

Click to view original post